iLoF is a digital health company that focuses on accelerating personalized drug discovery and development. The company offers a cloud-based library of optical fingerprints, powered by photonics and AI, which provides non-invasive tracking, screening, and stratification for drug discovery, adapted to each clinical trial's needs. iLoF primarily serves the healthcare and pharmaceutical industries. It was founded in 2019 and is based in London, England.
iLoF's Product Videos
iLoF's Products & Differentiators
Agnostic platform using Artificial Intelligence and photonics to screen patient from biological samples based on their biological profiles or disease biomarkers
Research containing iLoF
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned iLoF in 2 CB Insights research briefs, most recently on Feb 22, 2023.
Expert Collections containing iLoF
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
iLoF is included in 3 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 150
The winners of the second annual CB Insights Digital Health 150.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Latest iLoF News
May 18, 2023
London-headquartered startup Deployed that aims to address the challenges faced by organisations when it comes to contractually scoped projects has scored $4M in a seed funding round co-led by Amrock Ventures and US-based M12, Microsoft’s fund that also backed Inworld AI and iLoF recently. Further, the round saw participation from Portfolio Ventures, Mayfield Fund, HERmesa, and Angel Academe. Led by female founders Emma Rees and Kayleigh Kuptz, Deployed is focused on redefining the process of creating Statements of Work (SOWs) and planning projects. SOWs are vital documents that outline the objectives, scope of work, deliverables, timelines, and other crucial details of a project or engagement between a client and a service provider. By emphasising the importance of clear and comprehensive agreements, Deployed ensures that both parties have a solid understanding of the work to be executed, aiming to mitigate risks and enhance project success. With a staggering 65% of such projects failing to meet their original objectives and 1 in 10 ending up in legal or payment disputes, Deployed steps in to make a difference and use its latest round of funding to continue feature development, apply assisted writing and generative AI, and expand new and existing enterprise clients and boost hires. Launched in 2020 by Emma Rees, Kayleigh Kuptz and Jamie Gannaway, Deployed is carving out a distinct category in the realm of Scope Authoring for service contracts. While companies like Docusign excel in signature management, Ironclad specialises in contract management, Monday.com focuses on project management, and Vndly addresses vendor management, Deployed claims to stand as an innovative player within this broader ecosystem. Emma Rees, CEO and co-founder of Deployed, said: “It’s empowering to be part of the “2% of the 2%” (only 2% of VC investment goes to majority female founders and of that, less than 2% is in Enterprise SaaS). With most corporate work now globally distributed, project based and delivered by third parties, we need a new way to engage for services. We started Deployed to help everyone define work better and align on clear objectives early on”. Hugo Chardon, co-Founder of Amrock Ventures, said: “I was taken from the very first pitch that this was solving a problem that has been slipping through the gaps of corporate governance. It was very clear that the founding team, Emma, Kayleigh, and Jamie, were a winning one, bringing deep expertise and a balanced mindset.” “Deployed is a category defining startup that reimagines the Enterprise Resource Planning stack to stop project failure from the start. We are delighted to support the Deployed team and follow on with funding,” said Peter Berg, Managing Partner at M12. James Pringle, VC at Portfolio Ventures says “Our investment in Deployed was based on their strong product-market fit, notable growth trajectory, and their focus on addressing an underserved market segment.” Simplifies writing, editing, and publishing Statements of Work In simple terms, Deployed provides a platform that brings together different teams involved in the process of requesting and procuring services. This includes requestors of services, procurement teams, legal teams, and compliance teams. The platform offers an easy-to-use editor interface where these teams can collaborate and navigate through the workflow from the initial request to the final signature. It streamlines the process, making it more efficient and convenient for all parties involved. Clients leveraging the Deployed platform are experiencing significant advantages by digitising their workflows, which were previously reliant on Word documents and email exchanges. Through this transformation, clients have reported a remarkable 20% reduction in costs, achieved a 5x faster time to sign, and witnessed a 10x increase in project success rates. These improvements can be attributed to the platform’s ability to more accurately scope work on every statement of work, offering clients enhanced efficiency and productivity throughout their project lifecycles. Deployed currently serves a roster of prominent enterprise clients, such as Randstad Sourceright, Talent Solutions TAPFIN, and Roche. Additionally, in recognition of its accomplishments in the field of enterprise technology, Deployed was honored with the global Melinda Gates Female Founders award for the year 2020.
iLoF Frequently Asked Questions (FAQ)
When was iLoF founded?
iLoF was founded in 2019.
Where is iLoF's headquarters?
iLoF's headquarters is located at Unit 6 Queens Yard, White Post Lane, London.
What is iLoF's latest funding round?
iLoF's latest funding round is Seed VC - II.
How much did iLoF raise?
iLoF raised a total of $8.17M.
Who are the investors of iLoF?
Investors of iLoF include M12, re.Mind Capital, Charlie Songhurst, Faber Ventures, ERDF and 12 more.
Who are iLoF's competitors?
Competitors of iLoF include lino Biotech and 4 more.
What products does iLoF offer?
iLoF's products include iLoF.
Compare iLoF to Competitors
Cx Precision Medicine provides diagnostic screening treatments for patients affected with Alzheimer's disease. The company provides diagnostics for new and existing medications to help physicians determine appropriate patient prescribing for the treatment of Alzheimer's disease. It was founded in 2016 and is based in Fort Worth, Texas.
SYNAPS Dx is a company focused on Alzheimer's Disease diagnostics within the healthcare sector. The company provides scientific data to healthcare professionals to identify Alzheimer's Disease and distinguish it from other forms of dementia. The primary customers of SYNAPS Dx are healthcare professionals and institutions within the healthcare industry. It was founded in 2016 and is based in Rockville, Maryland.
Probius provides multi-scale biochemical phenotyping in a limited sample volume. It offers an all-electronic platform for fingerprinting biological specimens in preclinical and food safety applications. It was founded in 2016 and is based in Fermont, California.
Lasers4Life seeks to develop a method based on the unique properties of ultrashort laser pulses that will enable doctors to diagnose cancers at the earliest possible stage.
Pre Diagnostics is a Norwegian diagnostic company that seeks to create value for patients, partners, and investors by developing patient-friendly, in-vitro diagnostic (IVD) products for early detection of diseases. The company's proprietary concept is built upon the scientific premise that a disease evokes systemic responses in macrophages unique to that disease which can be accurately measured in the blood samples of patients.
C2N Diagnostics is a molecular diagnostics company. It offers sensitive mass spectrometry-based identification, quantification, and monitoring of proteins, protein fragments, and other biomolecules implicated in human neurological diseases. The company was founded in 2007 and is based in Saint Louis, Missouri.